Inactive Instrument

Harpoon Therapeutics, Inc. Stock




Biotechnology & Medical Research

Dynamic Chart

Latest transcript on Harpoon Therapeutics, Inc.

Managers TitleAgeSince
Director of Finance/CFO 62 19-03-31
Chief Tech/Sci/R&D Officer - 22-10-31
Chief Tech/Sci/R&D Officer 56 18-09-30
More insiders
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in the developing a T cell engager that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient's own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. The Company is developing a pipeline of T cell engagers using its TriTACs technology, focused on the treatment of solid tumors and hematologic malignancies. It has also nominated its clinical candidate using its ProTriTAC platform, a prodrug version of its TriTAC platform, designed to expand the target space for T cell engagers and bring the benefits of TriTACs to the patients. The Company's TriTAC product candidates include HPN217, and HPN328. The Company's ProTriTAC product candidate include HPN601, which is being developed for the treatment of multiple solid tumor indications.
More about the company